News

Imaging with ⁹⁹ᵐTc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery

15/03/2024

London, UK, 15 March 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that preliminary data has been presented from the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) imaging study, indicating that ⁹⁹ᵐTc-maraciclatide is capable of imaging superficial peritoneal endometriosis, the earliest stage of the disease. The data was presented today by Dr Tatjana Gibbons, an investigator on the study from the University of Oxford, in an oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada.

View News Article

⁹⁹ᵐTc-Maraciclatide Phase I Data Published in Nuclear Medicine Communications

14/03/2024

London, UK, 14 March 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ⁹⁹ᵐTc-maraciclatide, announces the publication of Phase I data demonstrating the safety, biodistribution and radiation dosimetry of ⁹⁹ᵐTc-maraciclatide in the April 2024 edition of Nuclear Medicine Communications.

View News Article

Preliminary Data to be Presented Evaluating ⁹⁹ᵐTc-Maraciclatide as a New Imaging Marker for Endometriosis

19/01/2024

London, UK, 19th January 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on the preliminary data from the first cohort of patients in the “Detecting Endometriosis expressed integrins using technetium-99m” imaging (DETECT) study, has been accepted for oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada.

View News Article

Development of a Deep Learning Approach for Analysing Scans of Rheumatoid Arthritis Patients using ⁹⁹ᵐTc-Maraciclatide Presented at the IEEE Nuclear Science Symposium and Medical Imaging Conference 2023

8/11/2023

London, UK, 8 November 2023, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster is being presented at the Institute of Electrical and Electronics Engineers Nuclear Science Symposium and Medical Imaging Conference 2023 taking place from 4 to 11 November in Vancouver, Canada.

View News Article

The Development of a Deep Learning Model to Classify Inflammation from ⁹⁹ᵐTc-Maraciclatide Scans Presented at the BNMS Autumn Meeting 2023

31/10/2023

London, UK, 31 October 2023, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster titled “Automatic Classification of Inflamed Joint Regions in Rheumatoid Arthritis using Deep Networks with ⁹⁹ᵐTc-Maraciclatide Imaging” is being presented at the British Nuclear Medicine Society meeting taking place on 31 October in London.

View News Article

AI methods for Automated Identification of Regions of Inflammation from ⁹⁹ᵐTc-Maraciclatide Imaging Presented at the World Molecular Imaging Congress 2023

09/09/2023

London, UK, 9 September 2023, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster titled “Automatic segmentation of regions of inflammation using deep neural networks for ⁹⁹ᵐTc-Maraciclatide gamma camera imaging of rheumatoid arthritis” is being presented at the World Molecular Imaging Society meeting taking place from 5-9 September in Prague, Czech Republic.

View News Article

Generative Modelling Methods for ⁹⁹ᵐTc-Maraciclatide Presented at the Institute of Electrical and Electronics Engineers (IEEE) Medical Imaging Conference 2022

10/11/2022

London, UK, 10 Nov 2022, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), the clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that an abstract titled ‘Single-Shot Generative Modelling for ⁹⁹ᵐTc-Maraciclatide Imaging’ is being presented today at the IEEE Medical Imaging Conference taking place 5-12 November in Milan, Italy.

View News Article

Serac Healthcare Partners with University of Oxford to Evaluate the Potential of ⁹⁹ᵐTc-Maraciclatide to Diagnose Endometriosis Non-Invasively

07/06/2022

Serac Healthcare Ltd is working with the University of Oxford to investigate whether an experimental image marker (⁹⁹ᵐTc-maraciclatide) that binds to areas of inflammation can be used to visualise endometriosis using a 20-minute scan.

View News Article (PDF)

James McCutcheon FCCA, Appointed Chief Financial Officer

01/11/2021

Please join us in welcoming James to the Serac Healthcare team. James is an experienced commercial and finance director with over 30 years’ experience in the pharmaceutical and medical device sectors, having held senior finance positions in both large multinationals, as well as smaller fast growing SMEs.

Julie Davis, Appointed Head of Quality Management

01/08/2020

Please join us in welcoming Julie to the Serac Life Sciences team as Head of Quality Management. Julie’s career has been spent in life science and radiopharmaceutical drug discovery, most recently consulting with biotech start-ups including leading the development and implementation of operational processes and quality systems.

Jon Barnett PhD, Appointed Head of CMC and Supply Chain

06/07/2020

We are pleased to announce that Jon has joined Serac Healthcare Limited as Head of CMC and Supply Chain. With over 20 years’ experience on radiopharmaceutical and biopharmaceutical product development and commercial supply, Jon has extensive experience of leading global functional and cross-functional project / operational teams to deliver new products and life cycle improvements.

Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress 2020

01/06/2020

Results from a Phase II study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the European League Against Rheumatism (“EULAR”) Congress 2020. The oral presentation is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be delivered by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 110

Session: Diagnostics and imaging procedures (Oral Presentations)

View News Article

Druin Burch FRCP, Appointed Chief Scientific Officer (CSO)

01/05/2020

Serac Life Sciences continues to strengthen its management team with the appointment of Dr Druin Burch as Chief Scientific Officer (CSO). Druin is a Consultant Physician at the Oxford University Hospitals NHS Trust, and has three decades experience as a clinician, scientist and writer in the field of developing and testing medical technology.

Abstract for Presentation at the American Congress of Rheumatology (ACR) Congress 2019

07/11/2019

Results from an interim analysis of the first 25 patients enrolled in a study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the American College of Rheumatology (ACR) Congress. The poster is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be presented by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

Date: Sunday, November 10, 2019

Session Title: Imaging Of Rheumatic Diseases Poster I

Session Time: 9:00AM-11:00AM

View News Article

Pat Butler, Joins as Board Observer and Advisor.

10/06/2019

Pat, a qualified Chartered Accountant, is a director of Hikma Pharmaceuticals, Chairman of Aldermore Bank and was formerly a Senior Director at McKinsey & Co. He is also a Governor of the British Film Institute and a trustee of the Resolution Foundation.

Serac Healthcare founded to develop a molecular imaging agent to help rheumatologists manage treatment decisions in their patients with rheumatoid arthritis

27/06/2018

Serac Life Sciences Limited (SLS) announces the formation of a new company, Serac Healthcare Limited (SHC), which will develop and commercialise a novel molecular imaging agent for the detection of disease activity in rheumatoid arthritis (RA). SHC, a wholly-owned subsidiary of SLS, has acquired the molecular imaging agent maraciclatide from GE Healthcare. The goal of the company is to enable rheumatologists to “see disease activity” in the joints, informing clinicians and helping them deliver personalised care to their patients.

View News Article (PDF)